Fig. 5From: New approach to intermittent and mild asthma therapy: evolution or revolution in the GINA guidelines?Pro and con for using SABA and ICS-FORM as relivers. SABA short acting beta2 agonist, ICS inhaled corticosteroids, FORM formoterolBack to article page